PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
21.85 USD
-0.59 (-2.63%)
21.85 USD
0 (0%)
Overall PCRX gets a fundamental rating of 5 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. PCRX has only an average score on both its financial health and profitability. PCRX has a bad growth rate and is valued cheaply. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -8.29%, PCRX is doing good in the industry, outperforming 69.27% of the companies in the same industry.
PCRX has a Return On Equity of -16.82%. This is in the better half of the industry: PCRX outperforms 69.79% of its industry peers.
The Return On Invested Capital of PCRX (3.88%) is better than 81.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 15.46%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
With an excellent Operating Margin value of 9.90%, PCRX belongs to the best of the industry, outperforming 82.29% of the companies in the same industry.
PCRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 78.19%, PCRX belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.53, we must say that PCRX is in the distress zone and has some risk of bankruptcy.
PCRX's Altman-Z score of 1.53 is fine compared to the rest of the industry. PCRX outperforms 61.98% of its industry peers.
The Debt to FCF ratio of PCRX is 4.96, which is a neutral value as it means it would take PCRX, 4.96 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.96, PCRX belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.50, PCRX is doing worse than 60.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.53 |
ROIC/WACC0.52
WACC7.49%
2.3 Liquidity
A Current Ratio of 2.38 indicates that PCRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.38, PCRX is in line with its industry, outperforming 43.75% of the companies in the same industry.
A Quick Ratio of 1.91 indicates that PCRX should not have too much problems paying its short term obligations.
The Quick ratio of PCRX (1.91) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -1.92% in the last year.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -17.68% in the last year.
The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
The Earnings Per Share is expected to grow by 5.92% on average over the next years.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 5.45% on average per year.
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.14, the valuation of PCRX can be described as very cheap.
Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.13. PCRX is valued rather cheaply when compared to this.
PCRX is valuated cheaply with a Price/Forward Earnings ratio of 6.60.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.19% of the companies listed in the same industry.
PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.14 | ||
| Fwd PE | 6.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.31% of the companies listed in the same industry.
PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 91.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.39 | ||
| EV/EBITDA | 6.24 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.51
EPS Next 2Y1.59%
EPS Next 3Y6.02%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.85
-0.59 (-2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change-0.8%
Ins Owners0.81%
Ins Owner Change0.59%
Market Cap981.72M
Revenue(TTM)705.85M
Net Income(TTM)-127460000
Analysts76.92
Price Target38.15 (74.6%)
Short Float %13.48%
Short Ratio10.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)0%
PT rev (3m)-3.11%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)-2.4%
EPS NY rev (1m)0.14%
EPS NY rev (3m)-1.72%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.83%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.14 | ||
| Fwd PE | 6.6 | ||
| P/S | 1.39 | ||
| P/FCF | 8.39 | ||
| P/OCF | 7.3 | ||
| P/B | 1.3 | ||
| P/tB | 3.12 | ||
| EV/EBITDA | 6.24 |
EPS(TTM)3.06
EY14%
EPS(NY)3.31
Fwd EY15.16%
FCF(TTM)2.61
FCFY11.92%
OCF(TTM)2.99
OCFY13.7%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.51
Graham Number34.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexgc growth 3Y-34.27%
ROICexgc growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.53 |
F-Score5
WACC7.49%
ROIC/WACC0.52
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.14 and the Price/Book (PB) ratio is 1.3.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 5 / 10.